Abstract
Multiple myeloma (MM) is a B cell malignancy characterized by accumulation of plasma cells (PCs) in the bone marrow. Traditional methods for the detection of minimal residual disease (MRD) measure the presence of monoclonal immunoglobulin protein secreted by the malignant PCs. However, changes in the level of MRD in MM may span 6 logs, and methods with a high sensitivity and dynamic range are necessary for quantitating MRD in MM. The two main technologies used in MRD detection are flow cytometry and patient-specific reverse transcription (RT) PCR. Patient-specific RT-PCR has high sensitivity and may be beneficial in monitoring patients receiving allogeneic transplantation. However, for the MRD evaluation of autotransplants, where few patients achieve molecular remission, flow cytometry monitoring seems to be sufficient.
References
1.
Barlogie B, Jagannath S, Epstein J, Munshi N, Siegel D, Desikan KR, Feinman R, Hsu P-L, von Bremen K, Tricot G: Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997;34(suppl 1):67–72.
2.
Hansen OP, Galton DAG: Classification and prognostic variables in myelomatosis. Scand J Haematol 1985;35:10–19.
3.
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91–97.
4.
Davies FE, Rawstron AC, Owen RG, Morgan GJ: Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002;15/1:197–222.
5.
Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, Lopez-Berges C, Moro MJ, Hernandez J, Escribano L, Caballero D, Rozman M, San MJ: Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655–1665.
6.
Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658–2663.
7.
Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San MJ: Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 1996;95:489–493.
8.
Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 1994;84:2597–2603.
9.
Bakkus MH, Van Riet I, De Greef C, Van Camp B, Thielemans K: The clonogenic precursor cell in multiple myeloma. Leuk Lymphoma 1995;18/3–4:221–229.
10.
Deane M, Norton JD: Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. Br J Haematol 1990;74/3:251–256.
11.
Deane M, Norton JD: Immunoglobulin gene ‘fingerprinting’: An approach to analysis of B lymphoid clonality in lymphoproliferative disorders. Br J Haematol 1991;77/3:274–281.
12.
Bird JM, Russell NH, Samson D: Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors. Bone Marrow Transplant 1993;12:651–654.
13.
Bird JM, Bloxham D, Samson D, Marcus RE, Russell NH, Kelsey SM, Newland AC, Apperley JF: Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994;88/1:110–116.
14.
Corradini P, Voena C, Omede P, Astolfi M, Boccadoro M, Dalla-Favera R, Pileri A: Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993;7:1879–1882.
15.
Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B: Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992;80:1818–1824.
16.
Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596–1602.
17.
Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley AA: Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 1996;92:614–619.
18.
Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992;80:2326–2335.
19.
Ralph QM, Brisco M, Joshua DE, Brown R, Gibson J, Morley AA: Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain. Blood 1993;82/1:202–206.
20.
Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der DM, Wu V, Newman R, Lichtenstein AK, Berenson JR: Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995;155:2487–2497.
21.
Biggs DD, Kraj P, Goldman J, Jefferies L, Carchidi C, Anderson K, Silberstein LE: Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma. Clin Diagn Lab Immunol 1995;2/1:44–52.
22.
Rasmussen T, Poulsen TS, Honore L, Johnsen HE: Quantitation of minimal residual disease in multiple myeloma using an allele specific real-time PCR assay. Exp Hematol 2000;28:1039–1045.
23.
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Lofvenberg E, Nesthus I, Rodjer S: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000;95/1:7–11.
24.
Rasmussen T, Jensen L, Honoré L, Johnsen HE: Frequency and kinetics of polyclonal and clonal B-cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000;96:4357–4359.
25.
Kiel K, Cremer FW, Rottenburger C, Kallmeyer C, Ehrbrecht E, Atzberger A, Hegenbart U, Goldschmidt H, Moos M: Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:1019–1027.
26.
Billadeau D, Prosper F, Verfaillie C, Weisdorf D, Van Ness B: Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia 1997;11:1565–1570.
27.
Rasmussen T, Jensen L, Johnsen HE: The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma 2002;43:1075–1077.
28.
Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ: Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095–3100.
29.
San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, Hernandez J, Moro MJ, Fernandez-Calvo J, Diaz-Mediavilla J, Palomera L, Orfao A: Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853–1856.
30.
Lipinski E, Cremer FW, Ho AD, Goldschmidt H, Moos M: Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:957–962.
31.
Lemoli RM, Cavo M, Fortuna A: Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother 1996;5:339–349.
32.
Gazitt Y, Tian E, Barlogie B, Reading CL, Vesole DH, Jagannath S, Schnell J, Hoffman R, Tricot G: Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996;87:805–811.
33.
Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE: Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Eur J Haematol 2001;67/5–6:289–295.
34.
Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR: Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997;19:337–342.
35.
Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, Dipersio J, Anderson KC, Berenson J: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771–3779.
36.
Rasmussen T, Bjorkstrand B, Andersen H, Gaarsdal E, Johnsen HE: Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: A pilot study. Exp Hematol 2002;30/1:82–88.
37.
Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, Van Lint MT, Bacigalupo A, Santoro A, Musso M, Majolino I, Boccadoro M, Pileri A: Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17/1:208–215.
38.
Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, Lemoli RM, Benni M, Pagliani G, Bandini G, Tura S: Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000;96:355–357.
39.
Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Motta MR, Testoni N, Amabile M, Ottaviani E, Vianelli N, de Vivo A, Gozzetti A, Tura S, Cavo M: Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18:2273–2281.
40.
Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171–1177.
41.
Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G: Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells. Blood 1997;90:1960–1967.
42.
Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998;91:2459–2466.
43.
Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607–4610.
44.
Rasmussen T, Jensen L, Johnsen HE: The clonal hierarchy in multiple myeloma. Acta Oncol 2001;39:765–770.
45.
Billadeau D, Ahmann G, Greipp P, Van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023–1031.
46.
Corradini P, Boccadoro M, Voena C, Pileri A: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993;178:1091–1096.
47.
Bakkus MH, Van Riet I, Van Camp B, Thielemans K: Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994;87/1:68–74.
48.
Pilarski LM, Cass CE, Tsuro T, Belch AR: Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Curr Top Microbiol Immunol 1992;182:177–185.
49.
Bjorkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE: Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: A randomised phase II-study. Eur J Haematol 2003;70:379–383.
50.
Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B: Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease. Blood 1991;78:3021–3029.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
